Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 7:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Recurrent Glioblastoma
Interventions
Nivolumab 240 mg IV, Nivolumab 3 mg/kg, Ipilimumab 1 mg/kg, NovoTTF200A (Optune)
Drug · Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Miami, Florida
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 9 more
Conditions
Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
Optune, Gadolinium, Temozolomide, Stereotactic radiosurgery (SRS)
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Conditions
Glioma
Interventions
Optune device
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Glioblastoma, Cancer of Brain, Glioblastoma Multiforme, Brain Tumor
Interventions
Tumor Treating Fields, Temozolomide, Radiation Therapy
Device · Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Conditions
Glioblastoma Multiforme
Interventions
NovoTTF-100A device, Temozolomide
Device · Drug
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
Interventions
Bevacizumab, Optune, Brain MRI, Quality of Life Questionnaires
Drug · Device · Other
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Conditions
Glioblastoma
Interventions
Optune
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Temple, Texas
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 7 more
Conditions
Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, Grade III
Interventions
Tadalafil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
RECURRENT GLIOBLASTOMA, Brain Tumor
Interventions
Optune(NOVOTTF-100A)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Glioblastoma, Brain Neoplasms
Interventions
NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
Device · Procedure · Genetic
Lead sponsor
University of Florida
Other
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Conditions
Malignant Glioma
Interventions
NovoTTF
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glioblastoma
Interventions
Bevacizumab, PD-L1 t-haNK, N-803, Tumor Treating Fields (TTFields, 200 kHz)
Drug · Device
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
El Segundo, California • Fullerton, California • Newport Beach, California + 1 more
Completed Phase 1 Interventional Results available

HUMC 1612: Optune NovoTTF-200A System

NCT03128047
Conditions
High Grade Glioma, Ependymoma
Interventions
Optune NovoTTF-200A System
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
5 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Orlando, Florida • Hackensack, New Jersey
Conditions
Glioblastoma Multiforme
Interventions
Optune®
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
87
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 68 more
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Procedure · Biological · Device + 3 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
285
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
Conditions
Cancer of Brain and Nervous System
Interventions
NovoTTF100A, Bevacizumab, Temozolomide
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Active, not recruiting Phase 2 Interventional

Niraparib/TTFields in GBM

NCT04221503
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
Niraparib, Optune, Planned surgical resection
Drug · Device · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glioblastoma, Glioma, Gliosarcoma
Interventions
Bevacizumab, TTFields Therapy
Drug · Device
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
22 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
La Jolla, California • Orange, California • Miami, Florida + 8 more
Conditions
Melanoma With Brain Metastasis
Interventions
Optune, Nivolumab, Ipilimumab
Device · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Brain Cancer
Interventions
Optune (NovoTTF-100A)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 5 more
Conditions
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
Device · Combination Product
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Conditions
Small Cell Lung Cancer, Brain Metastasis
Interventions
NovoTTF-100A plus chemotherapy
Device
Lead sponsor
John Villano
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky